Oxurion NV (OXUR.BR)
EUR 0.18
(-3.5%)
EUR 0.18
(-3.5%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 104 Thousand EUR | 138.38% |
| 2022 | -271 Thousand EUR | -68.32% |
| 2021 | -161 Thousand EUR | -138.42% |
| 2020 | 418.99 Thousand EUR | 138.58% |
| 2019 | -1.08 Million EUR | -155.27% |
| 2018 | 1.96 Million EUR | -39.18% |
| 2017 | 3.23 Million EUR | 1342.41% |
| 2016 | 224 Thousand EUR | -97.19% |
| 2015 | 7.96 Million EUR | -13.16% |
| 2014 | 9.17 Million EUR | -91.38% |
| 2013 | 106.39 Million EUR | 47.9% |
| 2012 | 71.93 Million EUR | 3083.1% |
| 2011 | 2.26 Million EUR | -59.89% |
| 2010 | 5.63 Million EUR | 42.91% |
| 2009 | 3.94 Million EUR | -85.75% |
| 2008 | 27.67 Million EUR | 2452.95% |
| 2007 | 1.08 Million EUR | -46.6% |
| 2006 | 2.03 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -27 Thousand EUR | 0.0% |
| 2023 Q2 | -48 Thousand EUR | 0.0% |
| 2023 Q4 | 6000.00 EUR | 0.0% |
| 2023 FY | 104 Thousand EUR | 138.38% |
| 2022 FY | -271 Thousand EUR | -68.32% |
| 2022 Q2 | -104 Thousand EUR | 0.0% |
| 2022 Q4 | -167 Thousand EUR | 0.0% |
| 2021 Q2 | -329 Thousand EUR | 0.0% |
| 2021 Q4 | 168 Thousand EUR | 0.0% |
| 2021 FY | -161 Thousand EUR | -138.42% |
| 2020 FY | 418.99 Thousand EUR | 138.58% |
| 2020 Q4 | 584 Thousand EUR | 0.0% |
| 2020 Q2 | 359 Thousand EUR | 0.0% |
| 2019 Q2 | -1.59 Million EUR | 0.0% |
| 2019 Q4 | 511 Thousand EUR | 0.0% |
| 2019 FY | -1.08 Million EUR | -155.27% |
| 2018 Q2 | 2.63 Million EUR | 0.0% |
| 2018 Q4 | -670 Thousand EUR | 0.0% |
| 2018 FY | 1.96 Million EUR | -39.18% |
| 2017 Q4 | 2.48 Million EUR | 0.0% |
| 2017 FY | 3.23 Million EUR | 1342.41% |
| 2017 Q2 | 750 Thousand EUR | 0.0% |
| 2016 Q4 | -2.32 Million EUR | 0.0% |
| 2016 Q2 | 2.55 Million EUR | 0.0% |
| 2016 FY | 224 Thousand EUR | -97.19% |
| 2015 FY | 7.96 Million EUR | -13.16% |
| 2015 Q4 | 3.15 Million EUR | 0.0% |
| 2015 Q2 | 4.81 Million EUR | 0.0% |
| 2014 Q4 | 2.57 Million EUR | 0.0% |
| 2014 Q2 | 6.6 Million EUR | 0.0% |
| 2014 FY | 9.17 Million EUR | -91.38% |
| 2013 Q2 | 98.84 Million EUR | 0.0% |
| 2013 Q4 | 7.55 Million EUR | 0.0% |
| 2013 FY | 106.39 Million EUR | 47.9% |
| 2012 Q1 | 17.98 Million EUR | 0.0% |
| 2012 FY | 71.93 Million EUR | 3083.1% |
| 2012 Q4 | 26.59 Million EUR | 47.9% |
| 2012 Q2 | 17.98 Million EUR | 0.0% |
| 2012 Q3 | 17.98 Million EUR | 0.0% |
| 2011 Q4 | 17.98 Million EUR | 3083.1% |
| 2011 Q1 | 565 Thousand EUR | 0.0% |
| 2011 Q2 | 565 Thousand EUR | 0.0% |
| 2011 FY | 2.26 Million EUR | -59.89% |
| 2011 Q3 | 565 Thousand EUR | 0.0% |
| 2010 FY | 5.63 Million EUR | 42.91% |
| 2010 Q2 | 1.4 Million EUR | 0.0% |
| 2010 Q1 | 1.4 Million EUR | 0.0% |
| 2010 Q3 | 1.4 Million EUR | 0.0% |
| 2010 Q4 | 565 Thousand EUR | -59.89% |
| 2009 Q1 | 985.75 Thousand EUR | 0.0% |
| 2009 FY | 3.94 Million EUR | -85.75% |
| 2009 Q3 | 985.75 Thousand EUR | 0.0% |
| 2009 Q2 | 985.75 Thousand EUR | 0.0% |
| 2009 Q4 | 1.4 Million EUR | 42.91% |
| 2008 Q4 | 985.75 Thousand EUR | -85.75% |
| 2008 FY | 27.67 Million EUR | 2452.95% |
| 2008 Q1 | 6.91 Million EUR | 0.0% |
| 2008 Q2 | 6.91 Million EUR | 0.0% |
| 2008 Q3 | 6.91 Million EUR | 0.0% |
| 2007 Q3 | 271 Thousand EUR | 0.0% |
| 2007 Q4 | 6.91 Million EUR | 2452.95% |
| 2007 FY | 1.08 Million EUR | -46.6% |
| 2007 Q2 | 271 Thousand EUR | 0.0% |
| 2007 Q1 | 271 Thousand EUR | 0.0% |
| 2006 Q4 | 271 Thousand EUR | -46.6% |
| 2006 FY | 2.03 Million EUR | 0.0% |
| 2006 Q3 | 507.5 Thousand EUR | 0.0% |
| 2006 Q2 | 507.5 Thousand EUR | 0.0% |
| 2006 Q1 | 507.5 Thousand EUR | 0.0% |
| 2005 Q4 | 507.5 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 83.172% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 97.343% |
| Adocia SA | 1.38 Million EUR | 92.491% |
| Aelis Farma SA | 12.35 Million EUR | 99.158% |
| Biophytis S.A. | -803 Thousand EUR | 112.951% |
| Advicenne S.A. | 1.42 Million EUR | 92.707% |
| genOway Société anonyme | 20.1 Million EUR | 99.483% |
| IntegraGen SA | 5.01 Million EUR | 97.928% |
| Medesis Pharma S.A. | -2.66 Million EUR | 103.903% |
| Neovacs S.A. | 29.31 Thousand EUR | -254.779% |
| NFL Biosciences SA | -56.06 Thousand EUR | 285.502% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 95.169% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 107.328% |
| Sensorion SA | 3.78 Million EUR | 97.254% |
| Theranexus Société Anonyme | -4.63 Million EUR | 102.242% |
| TME Pharma N.V. | -127 Thousand EUR | 181.89% |
| Valbiotis SA | 2.66 Million EUR | 96.102% |
| TheraVet SA | -530.79 Thousand EUR | 119.593% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 91.792% |
| argenx SE | 925.49 Million EUR | 99.989% |
| BioSenic S.A. | 543 Thousand EUR | 80.847% |
| Celyad Oncology SA | 33 Thousand EUR | -215.152% |
| DBV Technologies S.A. | 4.15 Million EUR | 97.5% |
| Galapagos NV | 203.73 Million EUR | 99.949% |
| Genfit S.A. | 28.22 Million EUR | 99.632% |
| GeNeuro SA | -293.8 Thousand EUR | 135.398% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 94.784% |
| Innate Pharma S.A. | -4.12 Million EUR | 102.524% |
| Inventiva S.A. | 17.5 Million EUR | 99.406% |
| MaaT Pharma SA | 1.65 Million EUR | 93.716% |
| MedinCell S.A. | 9.28 Million EUR | 98.88% |
| Nanobiotix S.A. | 36.2 Million EUR | 99.713% |
| Onward Medical N.V. | -14.81 Million EUR | 100.702% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 99.254% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 95.33% |
| Pharming Group N.V. | 220.1 Million EUR | 99.953% |
| Poxel S.A. | 1000.00 EUR | -10300.0% |
| GenSight Biologics S.A. | 3 Million EUR | 96.533% |
| Transgene SA | -28.4 Million EUR | 100.366% |
| Financière de Tubize SA | -2.02 Million EUR | 105.124% |
| UCB SA | 3.34 Billion EUR | 99.997% |
| Valneva SE | 52.83 Million EUR | 99.803% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 103.36% |